Patents by Inventor Louis Plamondon

Louis Plamondon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof
    Patent number: 6794516
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: September 21, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: François Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Boronic ester and acid compounds, synthesis and uses
    Publication number: 20040167332
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: December 8, 2003
    Publication date: August 26, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Formulation of boronic acid compounds
    Publication number: 20040138411
    Abstract: The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic add compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic add anhydride compounds useful in the methods of the invention.
    Type: Application
    Filed: December 23, 2003
    Publication date: July 15, 2004
    Applicants: Government of U.S.A., represented by the Secretary Department of Health & Human Services, Millennium Pharmaceuticals, Inc.
    Inventors: Louis Plamondon, Louis Grenier, Julian Adams, Shanker Lal Gupta
  • Boronic ester and acid compounds, synthesis and uses
    Patent number: 6747150
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: June 8, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Formulation of boronic acid compounds
    Patent number: 6699835
    Abstract: The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: March 2, 2004
    Assignees: The United States of America as represented by the Department of Health and Human Services, Millennium Pharmaceuticals, Inc.
    Inventors: Louis Plamondon, Louis Grenier, Julian Adams, Shanker Lal Gupta
  • Boronic ester and acid compounds, synthesis and uses
    Publication number: 20030199561
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: March 19, 2003
    Publication date: October 23, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Synthesis of clasto-lactacystin beta-lactone and analogs thereof
    Publication number: 20030191322
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Application
    Filed: February 7, 2003
    Publication date: October 9, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Francois Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Boronic ester and acid compositions
    Patent number: 6617317
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: September 9, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof
    Patent number: 6566553
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: May 20, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: François Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Boronic ester and acid compounds, synthesis and uses
    Patent number: 6548668
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: April 15, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Treatment of infarcts
    Publication number: 20030069189
    Abstract: This invention is directed to treating ischemia by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF-&kgr;B via the ubiquitin proteasome pathway, or mixtures thereof.
    Type: Application
    Filed: April 8, 2002
    Publication date: April 10, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Brand, Alfred L. Goldberg, Louis Plamondon, Francois Soucy, Peter J. Elliott
  • Formulation of boronic acid compounds
    Publication number: 20020188100
    Abstract: The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.
    Type: Application
    Filed: January 25, 2002
    Publication date: December 12, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Louis Plamondon, Louis Grenier, Julian Adams, Shanker Lal Gupta
  • Boronic Ester and acid compounds, synthesis and uses
    Publication number: 20020173488
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: March 18, 2002
    Publication date: November 21, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Boronic ester and acid compounds, synthesis and uses
    Patent number: 6465433
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: October 15, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Synthesis of clasto-lactacystin beta-lactone and analogs thereof
    Publication number: 20020016355
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Application
    Filed: August 10, 2001
    Publication date: February 7, 2002
    Inventors: Francois Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Treatment of infarcts
    Publication number: 20010053760
    Abstract: This invention is directed to treating ischemia by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF-&kgr;B via the ubiquitin proteasome pathway, or mixtures thereof.
    Type: Application
    Filed: July 30, 2001
    Publication date: December 20, 2001
    Inventors: Stephen J. Brand, Alfred L. Goldberg, Louis Plamondon, Francois Soucy, Peter J. Elliott
  • Treatment of inflammatory and autoimmune diseases
    Publication number: 20010051654
    Abstract: This invention is directed to the treatment of inflammatory and autoimmune diseases by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF-&kgr;B via the ubiquitin proteasome pathway, or mixtures thereof. The invention is further directed to the treatment of inflammatory and autoimmune diseases by administering an effective combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF-&kgr;B via the ubiquitin proteasome pathway, or mixture thereof. Pharmaceutical compositions comprising a combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF-&kgr;B via the ubiquitin proteasome pathway, or mixture thereof are also contemplated within the scope of the invention.
    Type: Application
    Filed: January 26, 2001
    Publication date: December 13, 2001
    Inventors: Peter J. Elliott, Julian Adams, Louis Plamondon
  • Boronic ester and acid compounds, synthesis and uses
    Patent number: 6297217
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: October 2, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof
    Patent number: 6294560
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: September 25, 2001
    Assignee: Millennium Pharmaceuticals, Inc..
    Inventors: François Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Treatment of infarcts
    Patent number: 6271199
    Abstract: This invention is directed to treating ischemia by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF-&kgr;B via the ubiquitin proteasome pathway, or mixtures thereof.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: August 7, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J Brand, Alfred L. Goldberg, Louis Plamondon, Francois Soucy, Peter J. Elliott